Effect of Xolair on Airway Hyperresponsiveness
The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness
Sponsor: Creighton University
A PHASE4 clinical study on Allergic Asthma, this trial is ongoing. The trial is conducted by Creighton University and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE4
First recorded
Jan 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Creighton University
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Omaha, United States